Edwards Lifesciences (EW) Asset Writedowns and Impairment (2017 - 2026)

Edwards Lifesciences' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $123.6 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $123.6 million; the TTM figure through Mar 2026 stood at $357.6 million (changed N/A YoY), while the FY2025 annual figure was $186.9 million, changed N/A from the prior year.
• Asset Writedowns and Impairment was $123.6 million for Q1 2026 at Edwards Lifesciences, down from $146.9 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $146.9 million in Q4 2025 to a low of $40.0 million in Q3 2025.